Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]

DRUG2 trials

Sponsors

Thomas Benfield, Fundación Huésped

Conditions

HIV InfectionsHIV LipodystrophyHIV-1-infectionHivObesityOsteoporosisRenal InsufficiencyWeight Gain

Phase 4

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

Thomas BenfieldHiv, HIV Infections, HIV Lipodystrophy +4

Start: 2021-02-02End: 2023-02-02Target: 126Updated: 2021-05-27

Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women

RecruitingNCT07616739

Fundación HuéspedHIV-1-infection

Start: 2026-09-10End: 2028-10-15Target: 210Updated: 2026-09-18